Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01246206 · OUTCOME

Severity of Acute GVHD

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT · Source last updated 2018-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
% of participants with sever aGVHD
Interval / dispersion
95% Confidence Interval
Time frame
Assessed first 6 months post transplant

What was measured

Cumulative Incidence of grade III-V acute GVHD with relapse or NRM as competing risks

Analysis population: Those participants who contracted Acute GVHD

Groups in this outcome

Tacrolimus and Thymoglobulin

Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis Tacrolimus and Thymoglobulin: Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or "transplant." Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tacrolimus and Thymoglobulin20

Reported measurements

Source class 1
Values in % of participants with sever aGVHD · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Tacrolimus and Thymoglobulin10.0Not reported1.627.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.6
        upper Limit
        27.8
        value
        10.0
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Cumulative Incidence of grade III-V acute GVHD with relapse or NRM as competing risks
dispersion Type
95% Confidence Interval
groups
  1. description
    Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis Tacrolimus and Thymoglobulin: Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or "transplant." Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.
    id
    OG000
    title
    Tacrolimus and Thymoglobulin
param Type
NUMBER
population Description
Those participants who contracted Acute GVHD
reporting Status
POSTED
time Frame
Assessed first 6 months post transplant
title
Severity of Acute GVHD
type
PRIMARY
unit Of Measure
% of participants with sever aGVHD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice